Syringomyelia is frequently associated with Chiari malformation or one of many otherpathological conditions. Its co-occurrence with medulloblastoma is rare, and to our knowledge, only 4 patients have been reported, although some reports have documented on syringomyelia associated with intracranial processes or intramedullary tumor. The authors describe an unusual case of asymptomatic thoracic syringomyelia complicated by an intrasyringal hemorrhage in a child with medulloblastoma. This report illustrates that, although unusual, syringomyelia is a potential complication in the natural history of medulloblastoma, and the authors consider the possible pathogenesis of syrinx enlargement.

1.
Klekamp J: The pathophysiology of syringomyelia – Historical overview and current concept. Acta Neurochir 2002;144:649–664.
2.
Milhorat TH: Classification of syringomyelia. Neurosurg Focus 2000;8:1–6.
3.
Anegawa S, Hayashi T, Torigoe R, Iwaisako K, Higashioka H: Cerebellopontine angle meningioma causing asymptomatic syringomyelia – case report. Neurol Med Chir (Tokyo) 1997;37:624–626.
4.
D’Osvaldo DH, Otero JM, Mosconi JB, Oviedo JD: Regression of symptomatic syringomyelia after resection of posterior fossa tumour. Acta Neurochir (Wien) 2002;144:385–388.
5.
Karttunen A, Heikkinen E, Tuominen J, Jartti P: Secondary syringomyelia disappearing after removal of tentorial meningioma. Acta Neurochir (Wien) 2002;144:741–742.
6.
Kosary IZ, Shaked I, Tadmor R: Cervical syringomyelia associated with occipital meningioma. Neurology 1969;19:1127–1130.
7.
Lee M, Rezai AR, Wisoff JH: Acquired Chiari-I malformation and hydromyelia secondary to a giant craniopharyngioma. Pediatr Neurosurg 1995;22:251–254.
8.
Sheehan JM, Jane JA: Resolution of tonsilar herniation and syringomyelia after supratentorial tumor resection: case report and review of the literature. Neurosurgery 2000;47:233–235.
9.
Wolansky LJ, Malantic GP, Heary R, Maniker AH, Lee HJ, Sharer LR, Patel UJ: Preoperative MRI diagnosis of Lhermitte-Duclos disease: case report with associated enlarged vessel and syrinx. Surg Neurol 1996;45:470–476.
10.
Nishio S, Matsuno H, Fukui M, Tateishi J, Kitamura K: Cerebellar medulloblastoma associated with lumbosacral syringomyelia. J Neurol 1982;227:67–73.
11.
Poser CM: The Relationship between Syringomyelia and Neoplasm. Springfield, Thomas, 1956.
12.
Williams B, Timperley WR: Three cases of communicating syringomyelia secondary to midbrain gliomas. J Neurol Neurosurg Psychiatr 1976;40:80–88.
13.
Klekamp J, Samii M, Tatagiba M, Sepehrnia A: Syringomyelia in association with tumors of the posterior fossa. Pathophysiological considerations, based on observations on three related cases. Acta Neurochir (Wien) 1995;137:38–43.
14.
Tachibana S, Harada K, Abe T, Yamada H, Yokota A: Syringomyelia secondary to tonsillar herniation caused by posterior fossa tumors. Surg Neurol 1995;43:470–477.
15.
Hinokuma K, Ohama E, Oyanagi K, Kakita A, Kawai K, Ikuta F: Syringomyelia. A neuropathological study of 18 autopsy cases. Acta Pathol Jpn 1992;42:25–34.
16.
Narayan P, Barrow DL: Intramedullary spinal cavernous malformation following spinal irradiation. Case report and review of the literature. J Neurosurg 2003;98:68–72.
17.
Bidzinski J, Kahl-Kunstetter J: Chronic bleeding into the syringomyelic cavity (Gower’s syringal hemorrhage) (in Polish). Neurol Neurochir Pol 1975;9:415–417.
18.
Barnett HJM, Foster JB, Hudgson P (eds): Syringomyelia. Major Problems in Neurology. Philadelphia, Saunders, vol 1, 1973.
19.
Gowers WR: Lecture 8. Syringal Haemorrhage into the Spinal Cord. Lectures on Diseases of the Nervous System. 2nd series. London, Churchill, 1904, pp 200–220.
20.
Perot P, Feindel W, Lloyd-Smith D: Hematomyelia as a complication of syringomyelia: Gowers’ syringal hemorrhage. Case report. J Neurosurg 1966;25:447–451.
21.
Schenk VW: Haemorrhages in spinal cord with syringomyelia in a patient with haemophilia. Acta Neuropathol (Berl) 1963;27:306–308.
22.
Packer RJ, Sutton LN, Elterman R, et al: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994;81:690–698.
23.
Douglas JG, Barker JL, Ellenbogen RG, Geyer JR: Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: Efficacy and patterns of failure. Int J Radiat Oncol Biol Phys 2004;58:1161–1164.
24.
Paulino AC: Hypothyroidism in children with medulloblastoma: a comparison of 3,600 and 2,340 cGY craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 2002;53:543–547.
25.
Heikens J, Michiels EMC, Behrendt H, Endert E, Bakker PJM, Fliers E: Long term neuro-endocrine sequelae after treatment for childhood medulloblastoma. Eur J Cancer 1998;34:1592–1597.
26.
Lovely TJ, Buchheit WA: Syringomyelia as a postoperative sequelae of the resection of a chordoma of the clivus: case report. Neurosurgery 1991;28:431–433.
27.
Kasantikul V, Netsky MG, James AE: Relation of age and cerebral ventricle size to central canal in man. J Neurosurg 1979;51:85–93.
28.
Noble M, Dietrich J: Intersection between neurobiology and oncology: tumor origin, treatment and repair of treatment-associated damage. Trends Neurosci 2002;25:103–106.
29.
Phuphanich S, Jacobs M, Murtagh FR, Gonzalvo A: MRI of spinal cord radiation necrosis simulating recurrent cervical cord astrocytoma and syringomyelia. Surg Neurol 1996;45:362–365.
30.
Russo C, Fischbein N, Grant E, Prados MD: Late radiation injury following hyperfractioned craniospinal radiotherapy for primitive neuroectodermal tumor. Int J Radiat Oncol Biol Phys 1999;44:85–90.
31.
Reddick WE, Russel JM, Glass JO, Xiong X, Mulhern RK, Langston JW, Merchant TE, Kun LE, Gajjar A: Subtle white matter volume differences in children treated for medulloblastoma with conventional or reduced dose craniospinal irradiation. Magn Reson Imaging 2000;18:787–793.
32.
Brugieres P, Idy-Peretti I, Iffenecker C, Parker F, Jolivet O, Hurth M, Gaston A, Bittoun J: CSF flow measurement in syringomyelia. AJNR Am J Neuroradiol 2000;21:1785–1792.
33.
Ayuzawa S, Tsukada A, Enomoto T, Yasuda S, Uemura K, Yamada T, Matsumura A, Nose T: Intrasyringal hemorrhage of the cervical cord associated with Chiari type I malformation – case report. Neurol Med Chir (Tokyo) 1995;35:243–246.
34.
Roig C, Lopez-Pousa S, Ferrer I: Bleeding in syringobulbia. A fatal complication. Eur Neurol 1982;21:189–193.
35.
Henneberg, Koch M: Hämatomyelie bei Syringomyelie und zur Pathogenese der Syringomyelie. Berl Ges Psychiatr Nervenkr Sitzg. 1922;10:126–127.
36.
Muhonen MG, Menezes AH, Sawin PD, Weinstein SL: Scoliosis in pediatric Chiari malformation without myelodysplasia. J Neurosurg 1992;77:69–77.
37.
Wiart L, Dautheribes M, Pointillart V, Gaujart E, Petit H, Barat M: Mean term follow up of a series of post traumatic syringomyelia patients after syringe-peritoneal shunting. Paraplegia 1995;33:241–245.
38.
Williams B, Turner E: Communicating syringomyelia presenting immediately after trauma. A case description and some theoretical concepts. Acta Neurochirug (Wien) 1971;24:97–106.
39.
Sedzimir CB, Roberts JR, Occleshaw JV, Buxton PH: Gowers’ syringal haemorrhage. J Neurol Neurosurg Psychiatry 1974;37:312–315.
40.
Nagasawa S, Ohta T, Onomura T, Miyaji Y: Endoscopic observation of the syrinx in Chiari malformation – case report. Neurol Med Chir (Tokyo) 1993;33:572–574.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.